2020
HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model
Stockhammer P, Ho CSL, Hegedus L, Lotz G, Molnár E, Bankfalvi A, Herold T, Kalbourtzis S, Ploenes T, Eberhardt WEE, Schuler M, Aigner C, Schramm A, Hegedus B. HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. Lung Cancer 2020, 144: 20-29. PMID: 32353632, DOI: 10.1016/j.lungcan.2020.04.002.Peer-Reviewed Original ResearchConceptsALK tyrosine kinase inhibitorsCell linesALK fusion oncogeneDistinct resistance mutationsTreatment-naïve ALKMalignant pleural effusionPost-treatment tumorsLung cancer modelPan-HDAC inhibitorsNovel therapeutic approachesTyrosine kinase inhibitorsMesenchymal transition (EMT) markersLung adenocarcinoma modelTime of resistancePleural effusionALK inhibitionLung adenocarcinomaSubcutaneous xenograftsALK inhibitorsTherapeutic approachesCell line pairsCancer modelAdenocarcinoma modelHDAC inhibitionTransition markers
2019
Parallel Acquired Resistance Heterogeneity: Novel Patient Derived Synchronous Cell Pair with Distinct Mutations in an ALK-Translocated Lung Adenocarcinoma
Hegedüs B, Stockhammer P, Plönes T, Hegedüs L, Bankfalvi A, Aigner C. Parallel Acquired Resistance Heterogeneity: Novel Patient Derived Synchronous Cell Pair with Distinct Mutations in an ALK-Translocated Lung Adenocarcinoma. Pneumologie 2019, 73: 111-111. DOI: 10.1055/s-0039-1678389.Peer-Reviewed Original Research